Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NASDAQ:GNPX NASDAQ:SNSE NASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$7.54-12.2%$8.61$6.51▼$13.27$9.10M1.6595,045 shs3,218 shsGNPXGENPREX$0.28-2.3%$0.28$0.20▼$3.97$9.40M-0.54.19 million shs841,865 shsSNSESensei Biotherapeutics$7.84-2.2%$7.42$5.00▼$17.40$10.12M0.2745,640 shs4,387 shsSXTP60 Degrees Pharmaceuticals$1.44-4.6%$2.34$1.41▼$35.99$2.22M2.78694,042 shs474,953 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-10.57%-15.19%-15.23%-0.84%-8.45%GNPXGENPREX-2.33%0.00%-8.31%+15.38%-86.09%SNSESensei Biotherapeutics-2.24%-6.51%+4.81%-3.33%-44.20%SXTP60 Degrees Pharmaceuticals-4.64%-42.86%-33.33%-54.43%+23.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.3989 of 5 stars3.53.00.00.02.20.80.6GNPXGENPREX1.3518 of 5 stars0.02.00.04.73.30.00.6SNSESensei Biotherapeutics4.3644 of 5 stars3.73.00.04.81.11.71.3SXTP60 Degrees Pharmaceuticals2.7317 of 5 stars3.33.00.00.02.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00297.88% UpsideGNPXGENPREX 0.00N/AN/AN/ASNSESensei Biotherapeutics 3.33Buy$90.001,047.96% UpsideSXTP60 Degrees Pharmaceuticals 2.50Moderate Buy$7.00386.11% UpsideCurrent Analyst Ratings BreakdownLatest SXTP, SNSE, GNPX, and ADXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/12/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/27/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/11/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/2/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$100.006/2/2025SXTP60 Degrees PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.80 ➝ $7.005/24/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/10/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/1/2025SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K17.37N/AN/A$10.37 per share0.73GNPXGENPREXN/AN/AN/AN/A$0.15 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$30.52 per shareN/ASXTP60 Degrees Pharmaceuticals$300K7.06N/AN/A($6.38) per share-0.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A3,584.49%-54.27%-49.15%9/1/2025 (Estimated)GNPXGENPREX-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)SNSESensei Biotherapeutics-$30.16M-$23.00N/AN/AN/AN/A-66.72%-57.10%8/5/2025 (Estimated)SXTP60 Degrees Pharmaceuticals-$7.95M-$50.41N/AN/AN/A-1,947.30%N/A-174.90%8/13/2025 (Estimated)Latest SXTP, SNSE, GNPX, and ADXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SXTP60 Degrees Pharmaceuticals-$1.24N/AN/AN/A$0.32 millionN/A8/8/2025N/AGNPXGENPREX-$0.71N/AN/AN/AN/AN/A8/5/2025Q2 2025SNSESensei Biotherapeutics-$6.20N/AN/AN/AN/AN/A5/15/2025Q1 2025SXTP60 Degrees Pharmaceuticals-$1.31-$1.56-$0.25-$1.56$0.15 million$0.18 million5/12/2025Q1 2025GNPXGENPREX-$0.82-$0.26+$0.56-$0.26N/AN/A5/6/2025Q1 2025SNSESensei Biotherapeutics-$4.20-$5.40-$1.20-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AGNPXGENPREXN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A3.023.02GNPXGENPREXN/A1.941.94SNSESensei BiotherapeuticsN/A6.826.82SXTP60 Degrees PharmaceuticalsN/A3.142.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%GNPXGENPREX14.05%SNSESensei Biotherapeutics10.50%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%GNPXGENPREX8.47%SNSESensei Biotherapeutics23.20%SXTP60 Degrees Pharmaceuticals10.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableGNPXGENPREX2033.15 million30.34 millionNo DataSNSESensei Biotherapeutics401.26 million968,000Not OptionableSXTP60 Degrees Pharmaceuticals31.47 million1.32 millionNot OptionableSXTP, SNSE, GNPX, and ADXN HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public OfferingJuly 16 at 4:01 PM | globenewswire.com60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration ...July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public OfferingJuly 15, 2025 | globenewswire.com60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 BillionJuly 15, 2025 | globenewswire.com60 Degrees Pharmaceuticals' (SXTP) Sell (E+) Rating Reiterated at Weiss RatingsJuly 15, 2025 | americanbankingnews.comSXTP - 60 Degrees Pharmaceuticals Inc Valuation - MorningstarJuly 3, 2025 | morningstar.comM60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 SharesJune 6, 2025 | insidertrades.com60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026June 5, 2025 | nasdaq.com60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle FormatJune 4, 2025 | globenewswire.comBabesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees PharmaceuticalsJune 3, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces First Quarter 2025 ResultsMay 15, 2025 | globenewswire.comBabesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma SurveyApril 22, 2025 | globenewswire.comWhy 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?April 10, 2025 | insidermonkey.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comSixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public HealthApril 8, 2025 | globenewswire.com60 Degrees Pharmaceuticals, Inc.April 4, 2025 | uk.investing.com60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVFebruary 21, 2025 | accessnewswire.comA60 Degrees Pharmaceuticals announces 1-for-5 reverse stock splitFebruary 20, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSXTP, SNSE, GNPX, and ADXN Company DescriptionsAddex Therapeutics NASDAQ:ADXN$7.54 -1.05 (-12.22%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$7.90 +0.36 (+4.77%) As of 07/18/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.GENPREX NASDAQ:GNPX$0.28 -0.01 (-2.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.28 +0.00 (+1.12%) As of 07/18/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Sensei Biotherapeutics NASDAQ:SNSE$7.84 -0.18 (-2.24%) Closing price 07/18/2025 03:51 PM EasternExtended Trading$8.05 +0.21 (+2.68%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.44 -0.07 (-4.64%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.44 0.00 (0.00%) As of 07/18/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
